Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 19/20 | 0.67 |
| ▸ | THRB | P10828 | 19/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.59 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.59 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16919814 | 0.88 | THRA (0.68) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL2926289 | 0.86 | THRB (0.67) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21749414 | 0.86 | THRA (0.67) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL22668218 | 0.84 | THRB (0.67) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL24032552 | 0.83 | THRB (0.70) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632428 | 0.83 | THRA (0.66) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL22668215 | 0.83 | THRA (0.63) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21749381 | 0.83 | THRA (0.64) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL24375474 | 0.82 | THRA (0.61) | THRATHRBCYP2C9UGT1A1ABCG2 | |
| SCHEMBL21840300 | 0.80 | THRA (0.65) | THRATHRBCYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112805005-B | Thyroxine receptor beta agonist compounds | 拓臻股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3840755-B1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250236615-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2025-07-24 | — | — | US | disclosed |
| CN-113454069-B | 1,2, 4-Triazine-3, 5-dione compound, and preparation method and application thereof | 昆药集团股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-113045551-B | Compound serving as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-11964962-B2 | Substituted pyridazinone compound and use thereof | Shandong First Medical University & Shandong Academy Of Medical Sciences (CN) | 2024-04-23 | — | — | US | disclosed |
| US-20230167091-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | Shandong First Medical University & Shandong Academy Of Medical Sciences (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230167091-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | Shandong First Medical University & Shandong Academy Of Medical Sciences (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230089582-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | KPC PHARMACEUTICALS INC (CN) | 2023-03-23 | — | — | US | disclosed |
| EP-4140998-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | Shandong First Medical University & Shandong Academy of Medical Sciences (CN) | 2023-03-01 | — | — | EP | disclosed |
| CN-113454069-A | 1, 2, 4-triazine-3, 5-diketone compound and preparation method and application thereof | 昆药集团股份有限公司 | 2021-09-28 | — | — | CN | disclosed |
| EP-3840755-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2021-06-30 | — | — | EP | disclosed |
| WO-2021104288-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 昆药集团股份有限公司 | 2021-06-03 | — | — | WO | disclosed |
| CN-112805005-A | Thyroxine receptor beta agonist compounds | 拓臻股份有限公司 | 2021-05-14 | — | — | CN | disclosed |
| CN-112645936-A | Substituted pyridazinone compound and use thereof | 山东第一医科大学(山东省医学科学院) | 2021-04-13 | — | — | CN | disclosed |
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | Terns, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| WO-2020041741-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2020-02-27 | — | — | US | disclosed |
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885CYP2C9 3768/4885 |
| US-11964962-B2 | Substituted pyridazinone compound and use thereof | THRB, TPO, TSHR | THRA 4/4885THRB 1/4885CYP2C9 379/4885 |
| US-20230089582-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885CYP2C9 2058/4885 |
| US-20250236615-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885CYP2C9 3768/4885 |
| US-20230167091-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | THRB, TPO, TSHR | THRA 4/4885THRB 1/4885CYP2C9 379/4885 |
| US-10800767-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | THRA 2/4885THRB 1/4885CYP2C9 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.